Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22576353 | 0.87 | MAPK9 (0.36) | MAPK9MAPK10L3MBTL1POLB | |
| SCHEMBL558541 | 0.77 | MAPK9 (0.39) | MAPK9MAPK10POLB | |
| SCHEMBL21341478 | 0.76 | — | — | |
| SCHEMBL27523149 | 0.75 | MAPK9 (0.38) | MAPK9MAPK10POLB | |
| SCHEMBL5671975 | 0.74 | KCNA5 (0.35) | MAPK9MAPK10L3MBTL1 | |
| SCHEMBL17845765 | 0.74 | MAPK9 (0.33) | MAPK9MAPK10 | |
| SCHEMBL22065924 | 0.73 | MAPK9 (0.37) | MAPK9MAPK10POLB | |
| SCHEMBL20858109 | 0.73 | MAPK9 (0.37) | MAPK9MAPK10POLB | |
| SCHEMBL2018148 | 0.73 | MAPK9 (0.37) | MAPK9MAPK10POLB | |
| SCHEMBL28404695 | 0.73 | MAPK9 (0.37) | MAPK9MAPK10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350176-B1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2021-04-28 | — | — | EP | disclosed |
| US-10392373-B2 | Oxazole derivatives that inhibit Syk | AB SCIENCE (FR) | 2019-08-27 | — | — | US | disclosed |
| US-20190055230-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2019-02-21 | — | — | US | disclosed |
| EP-3122744-B1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-11-07 | — | — | EP | disclosed |
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | AB SCIENCE (FR) | 2018-08-21 | — | — | US | disclosed |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-06-28 | — | — | US | disclosed |
| EP-3144307-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB Science (FR) | 2017-03-22 | — | — | EP | disclosed |
| EP-3122744-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB Science (FR) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015144614-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-10-01 | — | — | WO | disclosed |
| WO-2009112439-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-17 | — | — | WO | disclosed |
| EP-2041067-A2 | CXER4 ANTAGONISTS INCLUDING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS | Emory University (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008854-A9 | CXCR4 ANTAGONISTS INCLUDING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS | UNIV EMORY (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008008854-A2 | CXCR4 ANTAGONISTS INCLUDING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | SYK, ZAP70, LCK | MAPK9 484/4885MAPK10 414/4885FFAR2 1518/4885 |
| US-20190055230-A1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | SYK, BTK, LCK | MAPK9 400/4885MAPK10 790/4885FFAR2 2406/4885 |
| US-10392373-B2 | Oxazole derivatives that inhibit Syk | SYK, BTK, LCK | MAPK9 348/4885MAPK10 801/4885FFAR2 2530/4885 |
| US-20180179195-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, ZAP70, LCK | MAPK9 484/4885MAPK10 414/4885FFAR2 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.